

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Fusen Pharmaceutical Company Limited

福森藥業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1652)

VOLUNTARY ANNOUNCEMENT

“DYDROGESTERONE TABLET” APPROVED FOR MARKETING

The board of directors (the “**Board**”) of Fusen Pharmaceutical Company Limited (the “**Company**“, together with its subsidiaries, the “**Group**”) is pleased to announce that “Dydrogesterone Tablet” (trademark: Yunmeiyan*孕美顏) developed by Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited (嘉亨(珠海橫琴)醫藥科技有限公司), a wholly-owned subsidiary of the Company, has obtained the approval for marketing from the National Medical Products Administration of the PRC for the treatment of diseases and/or symptoms arising from endogenous progesterone deficiency.

“Dydrogesterone Tablet” is an orally ingestible progestogen, used for the treatment of diseases and/or symptoms arising from endogenous progesterone deficiency, such as dysmenorrhea, endometriosis, secondary amenorrhea, irregular menstrual cycles, dysfunctional uterine bleeding, premenstrual syndrome, threatened or habitual miscarriage and infertility caused by luteal phase deficiency. It is also used to provide luteal phase support in assisted reproductive technology.

Dydrogesterone is a synthetic progestogen whose structure and function are most similar to those of natural progesterone. Compared with natural progesterone, it has higher bioavailability, lower dosing frequency and provides a better liver safety profile. Compared with traditional synthetic progestogens, it has no oestrogenic, androgenic or corticosteroid effects, and does not increase the risk of breast cancer.

“Dydrogesterone Tablet” is a Class B drug under the National Healthcare Security Administration* (國家醫療保障局). It is recommended by authoritative guidelines in the PRC, including the Guidelines for the Diagnosis and Treatment of Endometriosis, the Guidelines for the Diagnosis and Treatment of Amenorrhoea, and the Clinical Practice Guidelines for Progestogen Use in Pregnancy Maintenance and Luteal Phase Support, and is widely used in various gynecological and obstetric diseases. According to data from Menet, the sales revenue of Dydrogesterone Tablets in urban and county-level public hospitals, as well as urban pharmacies in the PRC in 2025 was approximately RMB2.5 billion in aggregate.

“Dydrogesterone Tablet” is another important product of the Group, which further enriches the Company’s product pipeline. The approval of this product marks a significant breakthrough for the Company in the area of gynecology/reproductive pipeline and will provide more therapeutic options for a wide range of patients.

By order of the Board
Fusen Pharmaceutical Company Limited
Cao Zhiming
Chairman, Chief Executive Officer and Executive Director

Hong Kong, 27 April 2026

As at the date of this announcement, the Board of the Company comprises Mr. Cao Zhiming (Chairman), Mr. Hou Taisheng, Mr. Chi Yongsheng and Ms. Meng Qingfen as executive Directors and Mr. Lee Kwok Tung Louis, Dr. To Kit Wa and Mr. Yu Ho Ming as independent non-executive Directors.

** for identification purpose only*